Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01291784 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | terminated | Phase 1 | 3 | John MascarenhasOTHER | 1 | Dec 8, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT01655875 | AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia(BMTAMD3100) | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT01426334 | Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate | terminated | Phase 1 | 4 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00943293 | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies | terminated | Phase 1 | 1 | University of ChicagoOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00923234 | Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes(AZALE) | terminated | Phase 1 | — | Technische Universität DresdenOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00672152 | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation(WT-1) | terminated | Phase 1 | 8 | Michael Morse, MDOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft | terminated | Phase 1 / Phase 2 | 15 | Duke UniversityOTHER | 0 | Nov 25, 2013 | clinicaltrials |
| NCT00985530 | Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00049582 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | terminated | Phase 1 | 88 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00042796 | Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT01265199 | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 29 | Ascenta TherapeuticsINDUSTRY | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00101088 | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00790855 | Bendamustine in Acute Leukemia and MDS | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01066468 | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 13, 2012 | clinicaltrials |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00430443 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | terminated | Phase 1 | 3 | Callisto PharmaceuticalsINDUSTRY | 1 | Aug 31, 2011 | clinicaltrials |
| NCT00839059 | Lenalidomide In Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 14 | University of UlmOTHER | 1 | Jul 29, 2011 | clinicaltrials |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | terminated | Phase 1 | 100 | ExelixisINDUSTRY | 1 | Apr 5, 2011 | clinicaltrials |
| NCT00486265 | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 47 | AstraZenecaINDUSTRY | 2 | Dec 21, 2010 | clinicaltrials |
| NCT00279773 | Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 | 34 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 30, 2010 | clinicaltrials |
| NCT00004058 | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder | terminated | Phase 1 | — | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jan 26, 2010 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 50 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 17, 2008 | clinicaltrials |
| NCT00126893 | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | terminated | Phase 1 | 36 | Celgene CorporationINDUSTRY | 1 | May 15, 2007 | clinicaltrials |
| NCT00219765 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients | terminated | Phase 1 / Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Nov 28, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Dec 8, 2014source: clinicaltrials